Omeros Corporation ($OMER) reported its financial results for the fourth quarter and for the full year. The company’s revenue for the quarter stood at 412.9 million, up 94 percent on year over year basis. Its full year revenue was reported at $41.6 million, jumping 208 percent over the revenue for the previous year. Omeros incurred loss of $19.6 million, or $0.45 per share in the fourth quarter, while its full year loss stood at $66.7 million, or $1.65 per share.

Omeros also provided updates for its various activities. It opened enrollment in Phase 3 clinical trial of OMS721 in patients with atypical hemolytic uremic syndrome during the year. The company also announced positive  data from Phase 2 clinical trials of OMS721 in both renal disorders and hematopoietic stem cell transplant-associated thrombotic microangiopathy.

The company also had a successful post-marketing clinical trial of OMIDRIA in pediatric patients undergoing cataract surgery. The company stock plunged over 22 percent in the past 12 months, however, it has shown strong performance this year. The price gained 15 percent during this time period. Omeros stock is expected to keep up its performance as the company expects to go ahead with its plans of boosting its revenue stream.